window.pageData = {"stock":{"_id":3000000024985,"stockCode":"024985","masterFundShortName":"华宝中证制药ETF发起联接","fundSecondLevel":"fof","stockType":"fund","areaCode":"cn","market":"a","tickerId":24985,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"华宝中证制药ETF发起联接A","name":"华宝中证制药交易型开放式指数证券投资基金发起式联接基金","pinyin":"hbzzzyjyxkfszszqtzjjfqsljjj","setUpAssetScale":2149839.89,"setUpDate":"2025-08-25T16:00:00.000Z","setUpShares":2149839.89,"inceptionDate":"2025-08-26T16:00:00.000Z","followedNum":0,"etfFundFlag":1,"feederFundFlag":1,"indexFundFlag":1,"managers":[{"name":"张放","stockType":"fund_manager","stockCode":"db20782836","exchange":"fm","tickerId":2606218000}],"targetFunds":[{"shortName":"华宝中证制药ETF(562050)","stockType":"fund","stockCode":"562050","exchange":"sh","tickerId":562050}],"hotMetrics":{"fss":{"stockId":3000000024985,"type":"fss","last_data_date":"2025-12-30T16:00:00.000Z","f_ins_h_s_r":0,"f_ind_h_s_r":1,"f_h_a":393},"fpr":{"stockId":3000000024985,"type":"fpr","f_cagr_p_r_fs_ssc":1508,"f_cagr_p_r_fs_ssrp":0.9887193098871931,"f_p_r_m1_ssc":1520,"f_p_r_m1_ssrp":0.869651086240948,"f_p_r_m3_ssc":1448,"f_p_r_m3_ssrp":0.9232895646164478,"f_p_r_fys_ssc":1364,"f_p_r_fys_ssrp":0.9493763756419662,"f_p_r_m6_ssc":1338,"f_p_r_m6_ssrp":0.9588631264023935},"fp":{"stockId":3000000024985,"type":"fp","last_data_date":"2026-06-23T16:00:00.000Z","f_cagr_p_r_fs":-0.17910142257701245,"f_p_r_m1":-0.02681388012618313,"f_p_r_m3":-0.06493355094427589,"f_p_r_fys":-0.1065938961906876,"f_p_r_m6":-0.12405809763022746,"f_i_d":"2025-08-26T16:00:00.000Z"},"ff":{"stockId":3000000024985,"type":"ff","f_fr_d":"2025-12-30T16:00:00.000Z","f_m_fr":0.005,"f_c_fr":0.001,"f_mac_fr":0.006},"f_nlacan":{"stockId":3000000024985,"type":"f_nlacan","f_nv_d":"2026-06-23T16:00:00.000Z","f_nv":0.8021,"f_nv_cr":0.009057743112341088},"f_as":{"stockId":3000000024985,"type":"f_as","f_tas":3016170.3671999997,"f_tas_d":"2026-03-30T16:00:00.000Z"}},"masterSlaveFunds":[{"_id":3000000024986,"name":"华宝中证制药交易型开放式指数证券投资基金发起式联接基金","fundSecondLevel":"fof","stockType":"fund","areaCode":"cn","market":"a","status":"normal","indexFundFlag":1,"etfFundFlag":1,"feederFundFlag":1,"stockCode":"024986","tickerId":24986,"shortName":"华宝中证制药ETF发起联接C","currency":"CNY","__csrcFundId":15488,"exchange":"jj","masterFundFlag":null,"activeFundFlag":null,"lofFundFlag":null,"pensionTargetFlag":null,"classificationFlag":null,"closedEnd":null,"lastUpdated":"2025-09-05T23:15:50.640Z","inceptionDate":"2025-08-26T16:00:00.000Z","pinyin":"hbzzzyjyxkfszszqtzjjfqsljjj"}],"lastFsMetrics":{"latestTurnoverRate":0.056412672467648146,"latestTurnoverRateDate":"2025-12-30T16:00:00.000Z"}},"list":[{"_id":"69e8ecac1398d79843fea0b3","date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","stockId":3000000024985,"sao":"2026年一季度，宏观经济在政策的驱动下，实现了强劲开局，主要经济指标普遍回暖。供给端和基建投资表现强劲，工业生产显著提速，PPI通缩压力大幅缓解，为完成全年经济目标奠定了良好基础。宏观政策层面，财政政策承担了稳增长的主要角色，且靠前发力信号积极。多地积极启动2026年首批专项债发行，为重大项目提供了充足的资金保障。中央预算内投资提速，国家发改委提前下达2026年第一批“国家重大战略实施和重点领域安全能力建设”项目清单和中央预算内投资计划。同时，财政与金融协同支持内需的政策出台，支持民间投资和促进消费。货币政策延续“适度宽松”的基调，但在操作上更显灵活和审慎，强调与财政政策的协同。海外方面，美以伊冲突显著推升全球经济不确定性，导致原油价格大幅提升，通胀压力上行，美联储降息预期推迟甚至讨论加息的可能。市场方面，A股在地缘冲突冲击下震荡下行，不同板块表现差异明显。2026年一季度，煤炭、石油石化、公用事业等行业表现较好，非银金融、商贸零售、美容护理等行业表现较弱。指数方面，市场上基准指数呈现分化，以中证A100指数和沪深300指数为代表的大盘蓝筹股指数，分别下跌了3.49%和3.89%，而作为中小盘代表的中证500指数和中证1000指数，分别上涨了2.03%与0.32%。2026年一季度，中证制药指数累计下跌了1.22%。　　本报告期本基金为正常运作期，在操作中，我们严格遵守基金合同，坚持既定的指数化投资策略，在指数权重调整和基金申赎变动时，应用指数复制和数量化技术降低冲击成本和减少跟踪误差。","lastUpdated":"2026-04-22T15:43:40.715Z","fund":{"_id":3000000024985,"__csrcFundId":15488,"stockCode":"024985","masterFundShortName":"华宝中证制药ETF发起联接","fundSecondLevel":"fof","stockType":"fund","areaCode":"cn","market":"a","tickerId":24985,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"华宝中证制药ETF发起联接(024985)","lastUpdated":"2026-06-01T04:08:30.793Z","name":"华宝中证制药交易型开放式指数证券投资基金发起式联接基金","pinyin":"hbzzzyjyxkfszszqtzjjfqsljjj","setUpAssetScale":2149839.89,"setUpDate":"2025-08-25T16:00:00.000Z","setUpShares":2149839.89,"inceptionDate":"2025-08-26T16:00:00.000Z","followedNum":0,"etfFundFlag":1,"feederFundFlag":1,"indexFundFlag":1,"managers":[{"stockCode":"db20782836","stockType":"fund_manager","exchange":"fm","tickerId":2606218000,"name":"张放"}]},"announcement":{"linkText":"华宝中证制药交易型开放式指数证券投资基金发起式联接基金2026年第一季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1473381","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69cc27b31dc8b83221c665d5","date":"2025-12-30T16:00:00.000Z","declarationDate":"2026-03-30T16:00:00.000Z","stockId":3000000024985,"sao":"2025年全年，中国宏观经济在美国加征关税等复杂外部环境下，完成了5%的增长目标。尤其是部分新质生产力行业，呈现出高景气状态，取得了新的突破。如人工智能、生物医药、机器人等行业创新成果竞相涌现，研发应用走在世界前列，也带动了整体经济的发展。国内一系列积极的经济政策持续发力，为经济健康运行提供了关键支撑。2025年财政政策在预算安排和工具运用上更加积极，通过提高赤字率与扩大债务规模，实施超常规逆周期调节，保持必要支出强度，发挥宏观政策的支撑作用，推动了全年经济平稳运行。货币政策在总量温和扩张基础上，以降准降息加结构性工具为主，配合财政加杠杆，提供了宽松的流动性环境。海外环境来看，特朗普2.0掀起新的关税风暴，全球贸易规则与供应链加速重构。但与此同时，美联储下半年连续3次降息，全球货币政策转为宽松，一定程度上缓解了全球流动性压力。展望后续，2026年作为“十五五”开局年，经济工作将更注重供需动态平衡，强调结构优化与新质生产力驱动。指数方面，全年市场上大部分基准指数收涨，小盘风格显著强于大盘，成长风格强于价值风格。2025年全年，以中证A100指数和沪深300指数为代表的大盘蓝筹股指数分别上涨了20.44%和17.66%；而作为中小盘股代表的中证500指数和中证1000指数分别上涨了30.39%和27.49%。2025年全年，中证制药指数累计上涨了9.38%。　　本基金成立于2025年8月26日，本报告期涵盖了基金的建仓期。我们在操作中严格遵守基金合同，坚持既定的指数化投资策略，在指数权重调整和基金申赎变动时，应用指数复制和数量化技术降低冲击成本和减少跟踪误差。","lastUpdated":"2026-03-31T19:59:47.016Z","mo":"宏观经济方面，展望2026年，作为“十五五”规划的开局之年，预计GDP增长目标仍将接近5%，宏观政策将保持积极基调并边际加力。在政策工具方面，财政政策有望进一步发力，且政策节奏有望向2026年上半年“前置”。货币政策端，考虑到低通胀环境下实际利率偏高，降息进程或将延续，同时更强调与财政协调、围绕扩大内需和科技创新精准滴灌。随着“人工智能+”行动深化，新质生产力正迈入规模化与产业化的关键阶段，有望成为中国经济的新增长极。同时，通过“反内卷”政策、治理低价无序竞争及淘汰落后产能，来改善传统行业利润水平和整体经济活力。证券市场方面，经历2025年估值修复与信心重塑后，随着险资等中长期资金入市机制完善，以及居民财富向权益类资产再配置趋势的形成，市场增量资金仍然值得期待。2026年市场结构性机会或将从主题与流动性驱动转向业绩驱动。　　行业层面，国内药企从传统仿制药向创新药的产业转型，从完全依赖国内市场到积极开发全球市场的方向变化，是未来很多年内都不可逆转的产业趋势。过去几年间，中国创新药企业的出海出现了巨大的突破，最根本的原因是因为中国的创新药资产经历过去多年的积累，产生了从量变到质变的转化。随着国内创新药不断被海外大药企认可，国内一级市场对创新药的投资热情重新被燃起，使得创新药企业的现金流得到巨大改善，后续创新药企有望继续维持高速增长。中证制药指数选取业务涉及中药、化学药和生物药的上市公司证券作为指数样本，以反映制药主题上市公司证券的整体表现，投资者可以关注。　　作为指数基金的管理人，我们将继续严格遵守基金合同，坚持既定的指数化投资策略，积极应对成分股调整和基金申购赎回，严格控制基金相对目标指数的跟踪误差，实现对中证信息技术应用创新产业指数的有效跟踪。","fund":{"_id":3000000024985,"__csrcFundId":15488,"stockCode":"024985","masterFundShortName":"华宝中证制药ETF发起联接","fundSecondLevel":"fof","stockType":"fund","areaCode":"cn","market":"a","tickerId":24985,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"华宝中证制药ETF发起联接(024985)","lastUpdated":"2026-06-01T04:08:30.793Z","name":"华宝中证制药交易型开放式指数证券投资基金发起式联接基金","pinyin":"hbzzzyjyxkfszszqtzjjfqsljjj","setUpAssetScale":2149839.89,"setUpDate":"2025-08-25T16:00:00.000Z","setUpShares":2149839.89,"inceptionDate":"2025-08-26T16:00:00.000Z","followedNum":0,"etfFundFlag":1,"feederFundFlag":1,"indexFundFlag":1,"managers":[{"stockCode":"db20782836","stockType":"fund_manager","exchange":"fm","tickerId":2606218000,"name":"张放"}]},"announcement":{"linkText":"华宝中证制药交易型开放式指数证券投资基金发起式联接基金2025年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1460829","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed4097fea5b3eb0544043","date":"2025-09-29T16:00:00.000Z","declarationDate":"2025-10-27T16:00:00.000Z","stockId":3000000024985,"sao":"2025年3季度，尽管外部关税扰动仍在、全球需求边际放缓，但中国宏观经济在“政策组合拳”护航下延续温和回升态势。7　月召开的中央政治局会议，强调“稳中求进”工作总基调，明确要求强化宏观政策逆周期调节，做好政策储备和相机抉择，适时推出新的增量工具。财政政策进一步加码，地方专项债发行节奏提速，货币政策保持适度宽松，通过降准、MLF　利率下调及结构性工具，保持流动性合理充裕，引导实体经济融资成本稳中有降。海外方面，美联储　9　月议息会议宣布降息　25　bp，全球流动性环境延续边际宽松。展望后续，国内财政政策预计将更加积极，货币政策将保持灵活适度，以支持经济的持续健康发展。后续考虑到美国关税政策的不确定性，经济复苏节奏可能受扰，同时市场波动可能增加。市场方面，A股整体呈现上涨行情，但不同板块表现差异明显。2025年3季度，通信、电子、电力设备等行业表现较好，银行、交通运输、石油石化等行业表现较弱。指数方面，市场上基准指数呈现普涨的情况，以中证A100指数和沪深300指数为代表的大盘蓝筹股指数分别上涨了20.56%和17.9%，而作为中小盘代表的中证500指数和中证1000指数分别上涨了25.31%和19.17%。中证制药指数累计上涨了14.38%。　　本基金成立于2025年8月26日，本报告期涵盖了基金的建仓期。我们在操作中严格遵守基金合同，坚持既定的指数化投资策略，在指数权重调整和基金申赎变动时，应用指数复制和数量化技术降低冲击成本和减少跟踪误差。","lastUpdated":"2026-03-09T14:07:05.169Z","fund":{"_id":3000000024985,"__csrcFundId":15488,"stockCode":"024985","masterFundShortName":"华宝中证制药ETF发起联接","fundSecondLevel":"fof","stockType":"fund","areaCode":"cn","market":"a","tickerId":24985,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"华宝中证制药ETF发起联接(024985)","lastUpdated":"2026-06-01T04:08:30.793Z","name":"华宝中证制药交易型开放式指数证券投资基金发起式联接基金","pinyin":"hbzzzyjyxkfszszqtzjjfqsljjj","setUpAssetScale":2149839.89,"setUpDate":"2025-08-25T16:00:00.000Z","setUpShares":2149839.89,"inceptionDate":"2025-08-26T16:00:00.000Z","followedNum":0,"etfFundFlag":1,"feederFundFlag":1,"indexFundFlag":1,"managers":[{"stockCode":"db20782836","stockType":"fund_manager","exchange":"fm","tickerId":2606218000,"name":"张放"}]},"announcement":{"linkText":"华宝中证制药交易型开放式指数证券投资基金发起式联接基金2025年第三季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1373206","linkType":"PDF","source":"csrc_pdf"}}]}